Should I buy or sell IN8bio stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INAB shares. View INAB analyst ratings or view top-rated stocks .

What is IN8bio's stock price target for 2024?

2 brokerages have issued 12 month price targets for IN8bio's stock. Their INAB share price targets range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,220.8% from the stock's current price. View analysts price targets for INAB or view top-rated stocks among Wall Street analysts .

How have INAB shares performed in 2023?

IN8bio's stock was trading at $2.31 at the beginning of 2023. Since then, INAB stock has decreased by 63.9% and is now trading at $0.8328. View the best growth stocks for 2023 here .

Are investors shorting IN8bio?

IN8bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 27,600 shares, a decrease of 51.0% from the October 31st total of 56,300 shares. Based on an average daily trading volume, of 108,700 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are sold short. View IN8bio's Short Interest .

When is IN8bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024. View our INAB earnings forecast .

How were IN8bio's earnings last quarter?

IN8bio, Inc. (NASDAQ:INAB) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.11.

(INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.

Who are IN8bio's major shareholders?

IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Voss Capital LLC (1.62%) and Rock Creek Group LP (0.47%). Insiders that own company stock include Emily Fairbairn, Jeremy R Graff, Kate Rochlin, Lawrence Lamb, Patrick Mccall, Trishna Goswami and William Tai-Wei Ho. View institutional ownership trends .

How do I buy shares of IN8bio?

Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

IN8bio Stock Price, News & Analysis (NASDAQ:INAB)

$0.83

+0.05 (+6.87%)

(As of 04:00 PM ET)

Compare

Today's Range: $0.77
▼
$0.88
50-Day Range: $0.69
▼
$1.23
52-Week Range: $0.65
▼
$3.95

Volume: 308,402 shs
Average Volume: 1.13 million shs
Market Capitalization: $26.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $11.00

IN8bio MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,220.8% Upside
$11.00 Price Target
Short Interest: Healthy
0.13% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.85
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$2,375 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.93) to ($0.82) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.59 out of 5 stars

Medical Sector

99th out of 949 stocks

Biological Products, Except Diagnostic Industry

13th out of 157 stocks

3.5

Analyst's Opinion

Consensus Rating
IN8bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.00, IN8bio has a forecasted upside of 1,220.8% from its current price of $0.83.
Amount of Analyst Coverage
IN8bio has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.13% of the float of IN8bio has been sold short.
Short Interest Ratio / Days to Cover
IN8bio has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in IN8bio has recently decreased by 50.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
IN8bio does not currently pay a dividend.
Dividend Growth
IN8bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INAB.

3.2

News and Social Media Coverage

News Sentiment
IN8bio has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for IN8bio this week, compared to 1 article on an average week.
Search Interest
Only 4 people have searched for INAB on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added IN8bio to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, IN8bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,375.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
33.00% of the stock of IN8bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 7.37% of the stock of IN8bio is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for IN8bio are expected to grow in the coming year, from ($0.93) to ($0.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of IN8bio is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of IN8bio is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
IN8bio has a P/B Ratio of 1.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About IN8bio Stock (NASDAQ:INAB)

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

INAB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

INAB Stock News Headlines

November 28, 2023 | finance.yahoo.com

Harnessing The Power Of Gamma-Delta T Cells In Cancer Therapy: IN8bio’s Innovative Approach

November 23, 2023 | finance.yahoo.com

Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisher

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 20, 2023 | finanznachrichten.de

IN8bio, Inc: IN8bio's INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

November 20, 2023 | finance.yahoo.com

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

November 15, 2023 | markets.businessinsider.com

Promising Future for IN8bio: Anticipated Data Presentations, Capital Raise, and Innovative Developments

November 10, 2023 | finance.yahoo.com

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology 28th Annual Meeting

November 9, 2023 | msn.com

IN8bio GAAP EPS of -$0.23

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 9, 2023 | finance.yahoo.com

IN8bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023 | morningstar.com

IN8bio Inc Ordinary Shares INAB

November 6, 2023 | finance.yahoo.com

How IN8bio Is Working To Reach Its Goal Of “Cancer Zero” – Making Cancer A Thing of The Past

November 2, 2023 | tmcnet.com

IN8bio to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology (ASH) Annual Meeting

November 1, 2023 | finance.yahoo.com

IN8bio to Participate at the 2023 Truist Securities BioPharma Symposium

October 13, 2023 | markets.businessinsider.com

Buy Recommendation for IN8bio: Anticipated Funding, Clinical Validation, and Key Developments Drive Positive Outlook

September 29, 2023 | markets.businessinsider.com

Analyst Maintains Buy Rating for IN8bio Based on Positive SITC Release and Promising R&D Developments

September 29, 2023 | finance.yahoo.com

IN8bio Announces Presentations at the Society for Immunology of Cancer (SITC) 38th Annual Meeting

September 26, 2023 | finance.yahoo.com

IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies on Thursday, October 12, 2023 in New York City

September 20, 2023 | seekingalpha.com

IN8bio director Graff Jeremy acquires 2,500 company shares

September 20, 2023 | finance.yahoo.com

IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

September 19, 2023 | finance.yahoo.com

IN8bio Strengthens Intellectual Property Portfolio with Newly Granted Global Patents

September 6, 2023 | finance.yahoo.com

IN8bio to Participate at the H.C. Wainwright 25th Annual Global Investment Conference

August 15, 2023 | finance.yahoo.com

IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference

August 13, 2023 | finance.yahoo.com

Companies Like IN8bio (NASDAQ:INAB) Could Be Quite Risky

August 11, 2023 | markets.businessinsider.com

IN8bio (INAB) Gets a Buy from H.C. Wainwright

August 11, 2023 | finanznachrichten.de

IN8bio, Inc: IN8bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update

August 11, 2023 | markets.businessinsider.com

Mizuho Securities Sticks to Their Buy Rating for IN8bio (INAB)

See More Headlines

Receive INAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IN8bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 4/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INAB
CUSIP: N/A
CIK: 1740279
Web: www.in8bio.com
Phone: 646-600-6438
Fax: N/A
Employees: 26
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $11.00
High Stock Price Target: $14.00
Low Stock Price Target: $8.00
Potential Upside/Downside: +1,311.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-28,520,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -152.81%
Return on Assets: -106.33%

Debt

Debt-to-Equity Ratio: 0.04
Current Ratio: 3.53
Quick Ratio: 3.53

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.56 per share
Price / Book: 1.39

Miscellaneous

Outstanding Shares: 31,990,000
Free Float: 21,434,000
Market Cap: $24.93 million
Optionable: Not Optionable
Beta: -0.22

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Tai-Wei Ho (Age 46)
Co-Founder, President, CEO & Director
Comp: $837k
Dr. Kate Rochlin Ph.D. (Age 42)
Chief Operating Officer
Comp: $565.4k
Dr. Trishna Goswami M.D. (Age 45)
Chief Medical Officer
Comp: $638.51k
Dr. Lawrence S. Lamb Ph.D. (Age 69)
Executive VP, Co-Founder & Chief Scientific Officer
Comp: $482.47k
Mr. Patrick McCall CPA (Age 40)
CFO & Secretary
Comp: $519.35k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INAB Stock Analysis - Frequently Asked Questions

Should I buy or sell IN8bio stock right now?: 2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IN8bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INAB shares.
View INAB analyst ratings or view top-rated stocks.
What is IN8bio's stock price target for 2024?: 2 brokerages have issued 12 month price targets for IN8bio's stock. Their INAB share price targets range from $8.00 to $14.00. On average, they anticipate the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 1,220.8% from the stock's current price.
View analysts price targets for INAB or view top-rated stocks among Wall Street analysts.
How have INAB shares performed in 2023?: IN8bio's stock was trading at $2.31 at the beginning of 2023. Since then, INAB stock has decreased by 63.9% and is now trading at $0.8328.
View the best growth stocks for 2023 here.
Are investors shorting IN8bio?: IN8bio saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 27,600 shares, a decrease of 51.0% from the October 31st total of 56,300 shares. Based on an average daily trading volume, of 108,700 shares, the short-interest ratio is presently 0.3 days. Approximately 0.1% of the company's stock are sold short.
View IN8bio's Short Interest.
When is IN8bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our INAB earnings forecast.

How were IN8bio's earnings last quarter?: IN8bio, Inc. (NASDAQ:INAB) released its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.11.
When did IN8bio IPO?: (INAB) raised $44 million in an IPO on Friday, July 30th 2021. The company issued 4,000,000 shares at a price of $10.00-$12.00 per share. B. Riley Securities served as the underwriter for the IPO.
Who are IN8bio's major shareholders?: IN8bio's stock is owned by many different institutional and retail investors. Top institutional investors include Voss Capital LLC (1.62%) and Rock Creek Group LP (0.47%). Insiders that own company stock include Emily Fairbairn, Jeremy R Graff, Kate Rochlin, Lawrence Lamb, Patrick Mccall, Trishna Goswami and William Tai-Wei Ho.
View institutional ownership trends.
How do I buy shares of IN8bio?: Shares of INAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:INAB) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial